gms | German Medical Science

60. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie (DGNN)

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie

26. - 28.08.2015, Berlin

Artikel

Artikel empfehlen

RNAscope: a new method to detect MGMT status?

Meeting Abstract

Suche in Medline nach

  • corresponding author presenting/speaker Irene Kleinlein - Institute of Pathology, Neuropathology, Würzburg, Germany
  • Vanessa Wild - Institute of Pathology, Wuerzburg, Germany
  • Silviu Sbiera - University Hospital of Würzburg, Department of Internal Medicine I/Endocrinology, Wuerzburg, Germany
  • Iuliu Sbiera - University Hospital of Würzburg, Department of Internal Medicine I/Endocrinology, Wuerzburg, Germany
  • Petra Herud - Institute of Pathology, Neuropathology, Würzburg, Germany
  • Camelia-Maria Monoranu - Institute of Pathology, Neuropathology, Würzburg, Germany

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie. 60th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN). Berlin, 26.-28.08.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. Doc15dgnnP57

doi: 10.3205/15dgnn81, urn:nbn:de:0183-15dgnn811

Veröffentlicht: 25. August 2015

© 2015 Kleinlein et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

MGMT promoter methylation is a strong prognostic biomarker in glioblastoma patients treated with temozolomide. Methylation-specific PCR and pyrosequencing are the most commonly used DNA-based diagnostic methods for promoter methylation. Both are time- and cost-intensive methods harboring limitations, e.g. due to amount of tumor tissue and bisulfite treatment.

In situ hybridization is an extremely powerful research tool for gene expression on DNA level and widely used in routine diagnostics, e.g. HER2-neu amplification status. Especially chromogenic in situ hybridization is a fast and cost-effective method, which could be easily evaluated on bright field microscopy.

RNAscope is a new and extremely sensitive, in situ hybridization based method to visualize RNA molecules, which is compatible with fresh frozen and formalin fixed paraffine embedded tissue and does not require RNA-free environment.

We assume that CpG-Island methylation of MGMT promoter resulting in transcriptional silencing, is mirrowed by lack of MGMT RNA expression, whereas unmethylated tumor tissue shows strong RNA expression visualized by chromogenic in situ hybridization.

Our aim is to investigate whether this bright field based in situ hybridization method might be an achievement to assess MGMT status.